| Autor: |
Schmitz KS; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands., Lange MV; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands., Gommers L; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands., Handrejk K; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands., Porter DP; Gilead Sciences, Foster City, CA 94404, USA., Alabi CA; Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14850, USA., Moscona A; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.; Center for Host-Pathogen Interaction, Columbia University Irving Medical Center, New York, NY 10032, USA.; Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY 10032, USA.; Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA., Porotto M; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.; Center for Host-Pathogen Interaction, Columbia University Irving Medical Center, New York, NY 10032, USA.; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy., de Vries RD; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands., de Swart RL; Department of Viroscience, Erasmus MC, 3015 GD Rotterdam, The Netherlands. |
| Abstrakt: |
Measles virus (MV) is a highly contagious respiratory virus responsible for outbreaks associated with significant morbidity and mortality among children and young adults. Although safe and effective measles vaccines are available, the COVID-19 pandemic has resulted in vaccination coverage gaps that may lead to the resurgence of measles when restrictions are lifted. This puts individuals who cannot be vaccinated, such as young infants and immunocompromised individuals, at risk. Therapeutic interventions are complicated by the long incubation time of measles, resulting in a narrow treatment window. At present, the only available WHO-advised option is treatment with intravenous immunoglobulins, although this is not approved as standard of care. Antivirals against measles may contribute to intervention strategies to limit the impact of future outbreaks. Here, we review previously described antivirals and antiviral assays, evaluate the antiviral efficacy of a number of compounds to inhibit MV dissemination in vitro, and discuss potential application in specific target populations. We conclude that broadly reactive antivirals could strengthen existing intervention strategies to limit the impact of measles outbreaks. |
